Serum cystatin C as a marker for early detection of chronic kidney disease and grade 2 nephropathy in Japanese patients with type 2 diabetes

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 10, 2012, Pages 1833-1839

  Suzuki, Yoshitake ^a   Matsushita, Kazuyuki ^a,b   Seimiya, Masanori ^a,b   Yoshida, Toshihiko ^a   Sawabe, Yuji ^a   Ogawa, Makoto ^b   Nomura, Fumio ^a,b  

^a CHIBA UNIVERSITY HOSPITAL   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Albumin creatinine ratio; Chronic kidney disease; Cystatin C; Diabetic nephropathy; Glomerular filtration rate

Indexed keywords

BETA 2 MICROGLOBULIN; CREATININE; CYSTATIN C; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; IMMUNOASSAY; JAPANESE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SCREENING TEST;

ASIAN CONTINENTAL ANCESTRY GROUP; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CREATININE; CYSTATIN C; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 84867811446     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2011-07771     Document Type: Article

References (26)

1. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 2005;67:2089-100.
2. Kohagura K, Tomiyama N, Kinjo K, Takishita S, Iseki K. Prevalence of anemia according to stage of chronic kidney disease in a large screening cohort of Japanese. Clin Exp Nephrol 2009;13:614-20.
3. Burkhardt O, Kielstein JT. A simplified three-times weekly daptomycin dosing regimen for chronic hemodialysis patients. Expert Rev Anti Infect Ther 2010;8:11-4.
4. Komada H, Moriwaki K, Kamae I, Fukagawa M. Towards costeffective strategies for treatment of chronic kidney disease mineral and bone disorder in Japan. Ther Apher Dial 2009;13:28-35.
5. Beladi MS, Hayati F, Alemzadeh AM, Valavi E, Cheraghian B, Shahbazian H, et al. Survival at 1, 3, and 5 years in diabetic and nondiabetic patients on hemodialysis. Iran J Kidney Dis 2010;4:74-7.
6. Tsukamoto Y. End-stage renal disease (ESRD) and its treatment in Japan. Nephrol Dial Transplant 2008;23:2447-50.
7. Kondo K. The organ transplant law of Japan - the past, the present, and the future. J Int Bioethique 2005;16:91-102.
8. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, et al. Modification of the modification of diet in renal disease (MDRD) study equation for Japan. Am J Kidney Dis 2007;50:927-37.
9. Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006;69:1264-71.
10. Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama study. Kidney Int 2005;68:228-36.
11. Shemesh D, Golbetz H, Kriss JP, Myers BD. Limitation of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985;28:830-8.
12. Bataille R, Durie BG, Grenier J. Serum β2-microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol 1983;55:439-47.
13. Gejyo F, Yamada T, Odani S, Honma N, Saito H, Suzuki Y, et al. A new form of amyloid protein associated with chronic hemodialysis was identified as β 2-microglobulin. Biochem Biophys Res Commun 1985;28:701-6.
14. Robert WS. Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail 2008;1:2-5.
15. Newman DJ. Cystatin C. Ann Clin Biochem 2002;39:89-104.
16. Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function. Clin Chem Lab Med 1999;37:389-95.
17. Matsuo S, Imai E, Horio M, Yamada Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-92.
18. Report of the Ministry of Health and Welfare of Japan. Stage classification of diabetic nephropathy. Ministry of Health and Welfare of Japan, editor. Vol. 1. Tokyo: Ministry of Health and Welfare, 1991:251-6.
19. Coll E, Botey A, Alvarez L, Poch E, Quinto L, Saurina A, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000;36:29-34.
20. Shimizu-Tokiwa A, Kobata M, Lo H, Kobayashi N, Shou I, Funabiki K, et al. Serum cystatin C is a more sensitive marker of glomerular function than serum creatinine. Nephron 2002;92:224-6.
21. Incerti J, Zelmanovitz T, Camargo JL, Gross JL, Azevedo MJ. Evaluation of tests for microalbuminuria screening in patients with diabetes. Nephrol Dial Transplant 2005;20:2402-7.
22. Araki S, Haneda M, Sugimoto T, Isono M, Isshiki K, Kashiwagi A, et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 2005;54:2983-7.
23. Rigalleau V, Lasseur C, Raffaitin C, Beauvieux MC, Barthe N, Chauveau P, et al. Normoalbuminuric renal-insufficient diabetic patients: a lower-risk group. Diabetes Care 2007;30:2034-9.
24. Shimizu A, Horikoshi S, Rinno H, Kobata M, Saito K, Tomino Y. Serum cystatin C may predict the early prognostic stages of patients with type 2 diabetic nephropathy. J Clin Lab Anal 2003;17:164-7.
25. Jeon YK, Kim MR, Huh JE, Mok JY, Song SH, Kim SS, et al. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci 2011;26:258-63.
26. Kimura T, Ikeda H, Fujikawa J, Nomura K, Aoyama T, Wada Y, et al. Usefulness of serum cystatin C in Japanese patients with type 2 diabetes mellitus and nephropathy. Diabetes Res Clin Pract 2009;83:58-61.